# Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC

> **NCT03910712** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 250 (estimated)

## Conditions studied

- Breast Cancer Female
- HER2-positive Breast Cancer
- Hormone Receptor Positive Malignant Neoplasm of Breast
- Metastatic Breast Cancer
- Breast Diseases
- Hormone Receptor Positive Tumor

## Interventions

- **DRUG:** Pyrotinib
- **DRUG:** Trastuzumab
- **DRUG:** Aromatase inhibitor

## Key facts

- **NCT ID:** NCT03910712
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2019-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03910712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03910712, "Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03910712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*